|Day's Range||53.88 - 54.33|
|52 Week Range||46.01 - 77.12|
|PE Ratio (TTM)||18.81|
|Dividend & Yield||1.56 (2.89%)|
|1y Target Est||N/A|
Bristol-Myers Squibb's (BMY) oncology and cardiovascular products were among the most prioritized brands in the company's total portfolio in 1Q17.
New Research Reports for Britol-Myers, Pricline & Phillips 66
Eliquis is a new blockbuster drug in Bristol-Myers Squibb’s portfolio, and its sales rose ~50% to $1.1 billion in 1Q17.